Holen Sie sich die Stockscreener-App
0.2273
1.73%
-0.004
Handel nachbörslich:
.22
-0.0073
-3.21%
Curanex Pharmaceuticals Inc Aktie (CURX) Neueste Nachrichten
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
Curanex (CURX) OKs 5.7M-share incentive plan and 1:10–1:50 reverse split - Stock Titan
Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to book forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to sales forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Enterprise value to revenue forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split - Stock Titan
Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curanex Pharmaceuticals Inc (CURX) Institutional Confidence - TradingKey
Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curanex Pharmaceuticals Inc - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks - Bez Kabli
Curanex Pharmaceuticals Inc (CURX) Sees Modest Gain as Shares Test Key LevelsTechnical Analysis Picks - The Legal Advocate
CURXCuranex Pharmaceuticals Inc Stock Price and Quote - Finviz
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - minichart.com.sg
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com - Investing.com South Africa
CURX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Curanex Advances Phyto-N Program and Expands Indications - TipRanks
Curanex Pharmaceuticals Advances Phyto-N Toward FDA Submission for Ulcerative Colitis and Expands Pipeline to Cancer Cachexia - Minichart
Curanex Pharmaceuticals advancing phyto-n toward a planned investigational new drug submission to FDA for ulcerative colitis in Q4 2026 - marketscreener.com
Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia - Stock Titan
Curanex Pharmaceuticals Advances Toward Q4 2026 IND Submission for Ulcerative Colitis and Expands Pipeline to Include Cancer Cachexia - Quiver Quantitative
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - The Manila Times
Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) — 10-Q Summary - TradingView
Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline - Stock Titan
Colitis drug edges toward FDA review as Curanex targets cancer wasting - Stock Titan
TradingKey - TradingKey
Curanex awaits quarterly results as investors monitor for potential updates, CURX shares steady in quiet trading session.Investment Signal Network - newser.com
Is Curanex (CURX) a once in a decade opportunity? (Volatility Increases) 2026-05-08Stock News - newser.com
Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com Nigeria
Curanex Granted Nasdaq Extension to Regain Listing Compliance - TipRanks
Curanex Pharmaceuticals given second Nasdaq bid-price compliance period through Nov. 2, 2026 - TradingView
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
Get insights into the top gainers and losers of Tuesday's after-hours session. - ChartMill
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with ... - Caledonian Record
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm - GlobeNewswire
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):